Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Study Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF to Epirubicin and Docetaxel + G-CSF as Neoadjuvant Treatment for Early HER-2 Negative Breast Cancer and Comparing Epirubicin, Docetaxel and Capecitabine + G-CSF ± Trastuzumab to Epirubicin and Docetaxel + G-CSF ± Trastuzumab as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer
Brief Summary: Primarily, this clinical investigation compares the rates (percentages) of pathological complete remissions attained at the time of final surgery following 6 cycles each of epirubicin + docetaxel + capecitabine-containing chemotherapy ± trastuzumab (in HER-2 positive disease) vs. epirubicin + docetaxel-containing chemotherapy ± trastuzumab (in HER-2 negative disease).


Options:
A: Arm Label: A (experimental group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Capecitabine, Drug: Trastuzumab | Arm Label: B (control group); Type: ACTIVE_COMPARATOR; Interventions: Drug: Epirubicin, Drug: Docetaxel, Drug: Trastuzumab | Intervention Type: DRUG; Name: Epirubicin; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): A (experimental group), B (control group) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): A (experimental group) | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): A (experimental group), B (control group)
B: Arm Label: Standard Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Treatment | Arm Label: Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: capecitabine | Intervention Type: DRUG; Name: Standard Treatment; Assigned to Arm(s): Standard Chemotherapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Capecitabine
C: Arm Label: Epi-CMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-CMF; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: cyclophosphamide, Drug: epirubicin hydrochloride, Drug: fluorouracil, Drug: methotrexate, Procedure: adjuvant therapy | Arm Label: Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Arm Label: Accelerated Epi-Capecitabine; Type: EXPERIMENTAL; Interventions: Biological: pegfilgrastim, Drug: capecitabine, Drug: epirubicin hydrochloride, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegfilgrastim; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Accelerated Epi-Capecitabine, Epi-Capecitabine | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: epirubicin hydrochloride; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Accelerated Epi-CMF, Epi-CMF | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): Accelerated Epi-CMF, Accelerated Epi-Capecitabine, Epi-CMF, Epi-Capecitabine
D: Arm Label: A Bev+Pac; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab and Paclitaxel | Arm Label: B Bev+Cap; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab and Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab and Paclitaxel; Assigned to Arm(s): A Bev+Pac | Intervention Type: BIOLOGICAL; Name: Bevacizumab and Capecitabine; Assigned to Arm(s): B Bev+Cap

Answer: A